By: Giulia Corradetti, MD, Martin David Harp, Hattie Hayes
Giullia Coradetti, MD, offered insight into her research on a post-hoc analysis based on the GATHER 2 clinical trial data for geographic atrophy and age-related macular degeneration.
The below transcript has been lightly edited for clarity.
Giullia Coradetti, MD:
Hi, I’m Giullia Coradetti, one of the scientists at Doheny Eye Institute. I’m very happy to be able to present my research at ARVO annual meeting here in Salt Lake City. This year, I’m presenting a poster on the aurora characterization using fundus autofluorescence. It is a post-hoc analysis based on the GATHER 2 clinical trial data for geographic atrophy and age-related macular degeneration. Aurora lesions were initially introduced by the CaM group, and have structural biomarkers on OCT and [are] considered as precursors of atrophy.